This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush….
MMED.E
Scientists don’t have all the answers—if they did they would be out of a job—and sometimes that answer isn’t good enough. Especially for people who are suffering. They want…
Mind Medicine (MMED.E) has worked together with University Hospital Basel’s Liechti Laboratory to discover and file and patent application in the United States for a neutralizer technology that will…
The long and short of it is that psychedelics aren’t here yet. There are plenty of companies in various stages of development, doing what they can to make various…
Mind Medicine (MMED.E) started enrolling candidates for further human safety trial studies of 18-MC, the company’s orally taken ibogaine derivative for the treatment of opioid addiction. Clinical studies for…
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped…
From the day it landed on the stock market, MedMen (MMEN.C) was a company that drew derision and ire based almost entirely on the decision of its founders to…